Numinus seeks Health Canada approval to start psychedelic product trial

Numinus Wellness has announced the submission of the clinical trial application (CTA) to Health Canada to commence the Phase I clinical trial of a naturally derived Psilocybe extract formulation, NBIO-01, for psychedelic-assisted therapies. 

Category Scientific / Research
Published in Clinical Trials Arena